SXI Life Sciences
7.037,32
PKT
+50,69
PKT
+0,73
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
22.08.19 | Alcon Neutral | JP Morgan Chase & Co. | |
22.08.19 | Roche Reduce | HSBC | |
06.08.19 | Roche buy | Deutsche Bank AG | |
05.08.19 | Roche overweight | Barclays Capital | |
30.07.19 | Roche buy | Goldman Sachs Group Inc. | |
29.07.19 | Novartis Neutral | UBS AG | |
29.07.19 | Roche overweight | JP Morgan Chase & Co. | |
29.07.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
29.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
26.07.19 | Roche buy | Deutsche Bank AG | |
26.07.19 | Roche Neutral | Credit Suisse Group | |
26.07.19 | Roche buy | UBS AG | |
25.07.19 | Roche buy | Jefferies & Company Inc. | |
25.07.19 | Roche Neutral | UBS AG | |
24.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
23.07.19 | Novartis Neutral | UBS AG | |
22.07.19 | Roche buy | Deutsche Bank AG | |
22.07.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
22.07.19 | Novartis Hold | HSBC | |
19.07.19 | Roche buy | Goldman Sachs Group Inc. | |
19.07.19 | Roche overweight | JP Morgan Chase & Co. | |
19.07.19 | Novartis Neutral | Credit Suisse Group | |
19.07.19 | Novartis Hold | Deutsche Bank AG | |
19.07.19 | Novartis Underweight | Barclays Capital | |
18.07.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
18.07.19 | Novartis Neutral | UBS AG | |
18.07.19 | Novartis Neutral | UBS AG | |
18.07.19 | Roche overweight | JP Morgan Chase & Co. | |
16.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
16.07.19 | Roche overweight | JP Morgan Chase & Co. | |
15.07.19 | Roche overweight | JP Morgan Chase & Co. | |
11.07.19 | Roche buy | Goldman Sachs Group Inc. | |
08.07.19 | Roche buy | Deutsche Bank AG | |
08.07.19 | Novartis Hold | Deutsche Bank AG | |
05.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
04.07.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
03.07.19 | Roche overweight | JP Morgan Chase & Co. | |
01.07.19 | Roche overweight | JP Morgan Chase & Co. | |
28.06.19 | Roche overweight | JP Morgan Chase & Co. | |
27.06.19 | Novartis Neutral | UBS AG |